Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women (ICE-002)

This study has been withdrawn prior to enrollment.
(Decision not to go forth with study.)
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
Rush University Medical Center
ClinicalTrials.gov Identifier:
NCT00984152
First received: May 7, 2009
Last updated: May 4, 2011
Last verified: May 2011
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: December 2013
  Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)